This presentation summarize the current challenges the pharmaceutical industry is confronting to creative innovative products.

1. B Y S O L C O L O N
PHARMA BIG CHALLENGE
The ability to create
innovative products

2. Thepharmaceutical
industryhasbeen a
big disruptorand
has enjoyedof many
yearsofstability,but
if they don't
innovate soon,they
will be disrupted
.

3. .
Add a little bit of body text
PwC surveyed 1,757 C-suite and executive-level respondents , across more
than 25 countries and 30 sectors who are responsible for overseeing
innovation within their company . The sample of 76 respondents from the
Pharma sector on 13 countries said that less than 14% of revenues are
coming from new products and services launched in the past years ,compared
to 25% for the top innovators . That's lower than in most other industries.
Managing Innovation

4. B I G D R I V E R S F O R
I N N O V A T I O N R I G H T
N O W
# 1
R&D HIGH COST
# 2
TECHNOLOGY
# 3
ADOPTION OF
NEW BUSINESS
MODELS
#4
REGULATORY
POLICY

5. HIGH COSTS OF
R&D
The pharma industry spends about
$140 billion a year in R&D .
For this investment we are getting
25 to 35 new drugs.
Some of them are profitable but
others are too marginal.

6. TECHNOLOGY
Technology is transforming
medicine,science and research tools.
The digitization of the medicine is
changing the way we practice it.
Massive volume of data generated by
mobile devices and biosensors will soon
give parallel insights into poor
understood diseases.
These amount of data will improve the
controlled trials helping to formulate
better hypotheses about what causes
diseases in much less time.

7. NEW BUSINESS
MODEL
The traditional big pharma
models carrries high costs .
Spend $4 billion to $10 billion in
R&D per ech drug they bring to
market.
Small pharma , do the same thing
for a few hundred million to a couple
of billions, 50%-90% cheaper.
Virtual pharma, networked models
are vying to do it better.
Some big pharma are getting the
message, leverage networked
innovation,embracing precompetitive
collaboration.

8. REGULATORY
POLICY
• Policy makers can change things quickly. US
government purchases around &billion worth of
drugs per year.
• Countries like Germany, UK, Canada where
governments are using their power as single payers
to tamp down prices and curtail reimbursements.
• FDA has recently implemented a regulatory
innovation- The Breakthrough Therapy
Designation-and is having an enormous impact in
innovation.
• Regulators understands that regulations must
evolve with science. This is needed for technologies
such as cell therapies, gene therapy, synthetic
biology, biosensors and digital health devices.

9. INNOVATION IS THE ONLY WAY TO WIN
Steve Jobs
"If the Pharma
industry does not
innovate,it will be
disrupted"

10. "THE ABILITY TO GENERATE IDEAS IS NOT MERELY A
FUNCTION OF THE MIND ,
BUT ALSO A FUNCTION OF BEHAVIOURS. IF WE CHANGE
OUR BEHAVIOURS WE CAN IMPROVE OUR CREATIVE
CAPACITY"
"TheInnovator'sDNA:MasteringtheFive SkillsofDisruptive
Innovators",HalGregersen,JeffeyDyer,ClaytonChristensen
Questioning Five Discovery
Skills
Observing
Networking
ExperimentingAssociating

11. thank you
References:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfmevent=reportSSearch.process
https://www.pwc.com/gx/en/pharma-life-sciences/assets/pwc-managing-innovation-pharma.pdf
https://www.forbes.com/sites/medidata/2014/10/06/the-next-wave-of-pharmaceutical-innovation-an-inter
view-with-bernard-munos/#48622e166651
http://www.claytonchristensen.com/books/innovators-dna-mastering-skills-disruptive-innovators/
Images Credits: https://www.swansonreed.com/wp-content/uploads/2015/05/Science-writing.jpg
https://www.google.com/url
Sol Colon
linkedin.com/in/solcolon
https://twitter.com/solcolonrios